Curevac N.v Stock News

CureVac (CVAC) dosed the first person in a phase 1 study of its seasonal influenza second-generation mRNA vaccine candidate CVSQIV, developed in collaboration

Shares of CureVac gained 2.6% in premarket trading on Thursday after the company said it began dosing participants in a Phase 1 clinical trial assessing an experimental mRNA-based influenza vaccine it developed with GlaxoSmithKline . The open-label study plans to enroll 240 adults. CureVac had previously tried to develop a COVID-19 vaccine but instead decided last year to scrap those plans and instead focus on developing a second-generation COVID-19 shot with GSK. CureVac''s stock has tumbled 83.7% over the past year, while the broader S&P 500 is up 17.3%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

Shares of CureVac undefined gained 2.6% in premarket trading on Thursday after the company said it began dosing participants in a Phase 1 clinical trial…

Shares of CureVac CVAC, +5.06% gained 2.6% in premarket trading on Thursday after the company said it began dosing participants in a Phase 1 clinical trial assessing an experimental mRNA-based influen

CureVac N.V. (CVAC) shares closed this week 23.6% lower than it did at the end of last week. The stock is currently down 51.3% year-to-date, down 82.3% over the past 12 months, and down 70.1% over the past five years. This week, the Dow Jones Industrial Average fell 1.6%, and the S&P 500 fell 3.5%. Trading Activity Shares traded as high as $20.70 and as low as $16.51 this week.Trading volume this week was 2.1% lower than the 10-day average and 22.1% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.5. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price lags the S&P 500 Index this week, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price lags the Dow Jones Industrial Average this week, lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 290.7% The company's stock price performance over the past 12 months lags the peer average by 159.7% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Shares of CureVac N.V. (NASDAQ: CVAC) closed nearly 15% down on Friday after BofA Securities said there isn’t much in the books this year for shareholders of the German biopharmaceutical company. Ge

Amid broadly bearish market sentiment, investors in CureVac and CVAC stock are in selling mode, as this stock receives a downgrade.

Adding to over a third of its YTD loss, CureVac <> has dropped more than a tenth in morning hours after Bank of America downgraded the German biotech to Underperform from

Shares of CureVac N.V. (NASDAQ: CVAC) closed nearly 15% down on Friday after BofA Securities said there isn't much in the books this year for shareholders of the German biopharmaceutical company.

There is limited upside from CureVac BV’s (NASDAQ: CVAC) COVID-19 vaccine and there are few catalysts from the rest of the company’s pipeline in 2022, according to BofA Securities. The CureVac Ana

Amid broadly bearish market sentiment, investors in CureVac and CVAC stock are in selling mode, as this stock receives a downgrade. The post CVAC Stock Alert: Why Is Vaccine Maker CureVac Plunging Tod

Revisions to a shareholder agreement are causing the German vaccine maker's shares to fall.

Revisions to a shareholder agreement are causing the German vaccine maker's shares to fall.

Ahead of J.P. Morgan Healthcare Conference, CureVac BV (NASDAQ: CVAC) outlined the timeline for its vaccine programs.

CureVac N.V. (CVAC) shares closed 6.3% lower than its previous 52 week low, giving the company a market cap of $6B. The stock is currently down 1.6% year-to-date, down 60.3% over the past 12 months, and down 39.6% over the past five years. This week, the Dow Jones Industrial Average rose 1.1%, and the S&P 500 rose 0.1%. Trading Activity Trading volume this week was 14.6% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.2. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -235.4% The company's stock price performance over the past 12 months lags the peer average by 101.4% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.